IQVIA (NYSE:IQV) Insider Keriann Cherofsky Sells 558 Shares

IQVIA Holdings Inc. (NYSE:IQV) insider Keriann Cherofsky sold 558 shares of the firm’s stock in a transaction on Wednesday, July 29th. The shares were sold at an average price of $245.21, for a total value of $136,827.18. Following the sale, the insider directly owned 2,989 shares of the company’s stock, valued at $732,932.69. This represents a 15.73% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

IQVIA Trading Down 1.1%

IQV stock opened at $235.09 on Friday. IQVIA Holdings Inc. has a one year low of $154.50 and a one year high of $251.36. The stock has a market cap of $38.70 billion, a price-to-earnings ratio of 29.17, a price-to-earnings-growth ratio of 2.01 and a beta of 1.20. The company has a fifty day moving average price of $194.75 and a two-hundred day moving average price of $187.20. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.75.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, July 28th. The medical research company reported $3.15 earnings per share for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company’s revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the firm earned $2.81 earnings per share. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts anticipate that IQVIA Holdings Inc. will post 11.6 EPS for the current year.

IQVIA declared that its Board of Directors has approved a share buyback plan on Thursday, May 7th that authorizes the company to repurchase $2.00 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 6.8% of its stock through open market purchases. Stock repurchase plans are often an indication that the company’s board believes its shares are undervalued.

Analyst Ratings Changes

Several research firms have recently commented on IQV. BMO Capital Markets upped their target price on IQVIA from $210.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday. Barclays reissued an “overweight” rating on shares of IQVIA in a report on Tuesday. Stifel Nicolaus boosted their price target on IQVIA from $220.00 to $276.00 and gave the company a “buy” rating in a research note on Wednesday. Weiss Ratings raised IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, July 15th. Finally, Mizuho increased their price objective on IQVIA from $215.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average target price of $241.88.

IQVIA News Summary

Here are the key news stories impacting IQVIA this week:

• Positive Sentiment: William Blair upgraded IQVIA to “strong buy,” adding to the favorable analyst outlook. Ticker Report article
• Positive Sentiment: Robert W. Baird raised its IQVIA price target to $287, implying substantial upside from the cited trading level. JPMorgan and Stifel Nicolaus also expressed expectations for further appreciation. American Banking News article on Baird price target American Banking News article on JPMorgan forecast American Banking News article on Stifel outlook
• Positive Sentiment: IQVIA’s second-quarter results exceeded expectations, with adjusted earnings of $3.15 per share versus the $3.03 consensus and revenue of $4.37 billion versus $4.30 billion expected. Revenue increased 8.7% year over year, reinforcing the company’s growth profile. IQVIA Q2 2026 earnings call summary
• Neutral Sentiment: Analysts maintain a “moderate buy” consensus, indicating generally favorable sentiment but not unanimous conviction. IQVIA analyst consensus article
• Negative Sentiment: Two insiders sold shares on July 29: Keriann Cherofsky sold 558 shares for approximately $136,827, while Eric Sherbet sold 5,000 shares for about $1.25 million. Although both retain meaningful holdings, the transactions may create short-term investor concern. SEC insider sale filing for Keriann Cherofsky SEC insider sale filing for Eric Sherbet

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Tema ETFs LLC raised its position in shares of IQVIA by 9.4% in the second quarter. Tema ETFs LLC now owns 3,370 shares of the medical research company’s stock valued at $651,000 after buying an additional 290 shares in the last quarter. Fulton Bank N.A. boosted its stake in shares of IQVIA by 2.9% in the second quarter. Fulton Bank N.A. now owns 6,118 shares of the medical research company’s stock valued at $1,182,000 after buying an additional 175 shares during the period. Franklin Street Advisors Inc. NC grew its position in IQVIA by 1.0% during the second quarter. Franklin Street Advisors Inc. NC now owns 100,198 shares of the medical research company’s stock worth $19,360,000 after buying an additional 1,002 shares in the last quarter. HF Advisory Group LLC increased its stake in IQVIA by 25.7% during the 2nd quarter. HF Advisory Group LLC now owns 9,095 shares of the medical research company’s stock worth $1,757,000 after acquiring an additional 1,861 shares during the period. Finally, Oliver Luxxe Assets LLC bought a new position in IQVIA during the 2nd quarter worth $3,589,000. 89.62% of the stock is owned by institutional investors.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.